Condition or Therapy: Leukemia and lymphoma
Category: Cancer and Blood Disorders

What is the goal of this study?

PLAT-05 is a first-in-the-nation pediatric phase 1 trial that tests the safety and feasibility of CAR T cells that have been reprogrammed to target CD19 and CD22 proteins simultaneously. CD19 and CD22 are expressed by most leukemia cells.

Our researchers developed PLAT-05 as an investigational treatment option that will hopefully lead to long-term remission for patients whose cancer expresses CD19 and CD22.

Who can join the study?

This study might be a good fit for children and young adults who:

  • Are ages 1 to 26 years old
  • Have relapsed or refractory pre-B acute lymphoblastic leukemia (ALL) or other CD19+ or CD22+ acute leukemia or CD19+ non-Hodgkin lymphoma. It is not open to young people with other leukemias or other childhood cancers.

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

What happens in the study?

You can read the complete PLAT-05 study protocol on

Who can I contact for information or to enroll?

Please email or call the research coordinator at 206-987-2106 to learn more about the study.

Study Location(s): Seattle Children's Hospital main campus
Principal Investigator: Dr. Rebecca Gardner